Safety of quadrivalent human papillomavirus vaccine administered routinely to females. - Wikidata - wikimedia - TriplyDB

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

http://www.wikidata.org/entity/Q33161840

about

Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Human papillomavirus vaccination: a case study in translational science Long-term efficacy and safety of human papillomavirus vaccination Safety of human papillomavirus vaccines: a review Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies Safety of human papillomavirus vaccines: a review.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer.Ethical considerations of universal vaccination against human papilloma virus Kaiser Permanente Vaccine Study Center: Highlights of 2009-2012.Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.High school females and those with other vaccinations most likely to complete the Human Papillomavirus vaccine Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer.Does intention to recommend HPV vaccines impact HPV vaccination rates?Sepsis, parenteral vaccination and skin disinfection.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.The most effective and promising population health strategies to advance human papillomavirus vaccination.Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series.Human Papillomavirus Vaccine and Postural Orthostatic Tachycardia Syndrome: A Review of Current Literature.Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.Why is it appropriate to recommend human papillomavirus vaccination as cervical cancer prevention?The human papillomavirus vaccination is not associated with risk of multiple sclerosis or other demyelinating diseases.Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine.Exploring Facilitators and Barriers to Initiation and Completion of the Human Papillomavirus (HPV) Vaccine Series among Parents of Girls in a Safety Net System.9-Valent human papillomavirus vaccine: a review of the clinical development program.T-cell receptor excision circle levels and safety of paediatric immunization: A population-based self-controlled case series analysis.Association between Human Papilloma Virus (HPV) vaccination and risk of Multiple Sclerosis: A systematic review.HPV vaccination rates remain low: cancer prevention community needs to continue promoting the vaccine's safety and efficacy, say experts.Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction.Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System.Statistical Power for Postlicensure Medical Product Safety Data Mining.Aluminium adjuvants used in vaccines versus placebo or no intervention Identifying and Overcoming Perceived Barriers of Providers towards HPV Vaccination: A Literature Review

P2860

Q26799634-243761C6-0F88-4187-A146-1FABC4A23D79 Q26853556-2DB62F6A-F731-454D-83DD-9D1400E67C58 Q28081156-20F58629-15D6-4047-B869-70075748D370 Q28082119-7D0AF81E-B3DC-4AB8-AEAE-C3C26425281B Q28300023-0494C54D-CEDC-4898-A299-F5E03289E5B6 Q30665207-8B8074EA-24C8-42AF-8934-16AD8950F2F1 Q33162724-3A4D11B6-BF1E-4B1F-B9C0-4CA12DA92C78 Q33166996-F49C69F1-1E5A-4119-B10E-9845C8DDCF63 Q33167424-5DCE2AE0-3B71-42A9-83EE-4563F4D6A098 Q33167702-E9889811-A21C-4256-A1CA-666545CF34E5 Q34686752-B1E779F5-D723-4E7E-B721-5F12D2D333C3 Q35141381-FFEB5E1A-B07E-402C-87C8-3D453BE69603 Q35890630-2431D2D9-1FBD-4211-957D-C42C9E3D9BE7 Q35927665-7D03911F-4F1C-4F94-80AB-4A85FDAED312 Q36127838-13241561-A803-452B-BA77-342EC8892945 Q36457330-FB2A7B2B-3AD5-45E6-A609-D71F34DD5FF1 Q36486428-BEF5253F-CC89-4ABC-911F-FC56D074FB29 Q36807320-DCD45F29-82A6-4198-9B20-5D9399209F53 Q37159643-E7BF1D62-CE92-46BB-9675-AEDED7BB7CB0 Q37375883-09DE6A1B-A5B1-48A1-A06B-A75E368110B4 Q38229304-16710358-9BA1-40EF-A33E-695D28AAF557 Q38555725-B3A6CB9A-89FB-4D24-AD57-88B7FED89E6C Q38586257-A781F344-5C52-4635-A03E-24D037EF357D Q38630935-248ED2D5-643D-4045-9D57-472FD1ED9CC7 Q38668821-E6816FAC-7906-4B11-81A4-338BC0D30AA0 Q38687916-B3573FAC-4F47-4AE9-A213-8B90F3EDE81E Q40593455-7BC5A726-196B-4DD2-8D3F-A038BC740DA1 Q41154562-C1F6CF50-042B-4B6A-AC07-2BE33AD8D3B5 Q41356971-9BE0D27C-40D3-405D-864C-80177202A04B Q46330367-27DC1C89-7D9B-4C0C-8EBE-9C8CADA218ED Q47650022-AB816D83-6EA3-4DB8-A8AA-60507458D963 Q49687633-4885070A-E93F-409C-86D5-2F779B45A378 Q50116225-8437800A-25EA-43E6-8D88-4A220A438B29 Q50542374-139C5C4A-0428-4BEF-8FF9-2E7B884F3874 Q51028052-E3413298-29DE-4CCD-A0E8-F3C649E048DD Q54262416-C15F0439-B89E-4B1B-9968-27B7805F6928 Q54938964-84863540-C0F7-487D-81A1-6CB69F57C02C Q54981091-9163973B-E520-4031-AF4A-90842419BBAD Q57389398-DFAB94B8-330C-41E9-8EA9-C8D4573A6A05 Q59104301-E3BF434E-67F0-48D1-8D4B-9FBEC59C6954

P2860

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

http://www.wikidata.org/entity/Q33161840

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@ast

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@en

type

label

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@ast

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@en

prefLabel

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@ast

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@en

P1433

Q33161840-83DF2AC7-F468-4B60-84A0-DEA4A4F9472F

P1476

Q33161840-4FE1C2B9-9174-41DB-B9BF-350552B55E50

P2093

Q33161840-0A49F1DA-C368-4C87-BEF2-8011A7925DFF

Q33161840-1DBA5B04-A2B8-4589-8CDB-664ACC379975

Q33161840-2DBB1062-AE85-4053-973A-53DCD79B317B

Q33161840-32E4B50B-2619-4B40-9D2D-02335DDE126A

Q33161840-35349C18-E9A5-4809-9398-3D8983A99622

Q33161840-394F4077-18DA-4B44-992C-AEDA7A4E9E09

Q33161840-3F179B92-601E-4F64-8962-08D5016FDFF5

Q33161840-6AF721CA-A8EF-4BA2-BCA9-2F6C2CE50DC5

Q33161840-B0FC8F5D-03E4-4974-9737-070BA8121EA6

Q33161840-CDF01ED9-56F4-42D9-9CAB-00F99F2831AE

P304

Q33161840-260936AB-0CD1-4F14-B8E5-EFD11A2B19A3

P31

Q33161840-4192DD1E-1000-4ABE-B906-7BF9AA95D639

P356

Q33161840-BA8A06DA-3795-4128-90E1-C9E8D0476FC7

P407

Q33161840-F4EF8AEE-0AAA-4FB6-8549-2DE8916BD79E

P433

Q33161840-DF17A551-D46D-4A8C-A1FB-4D5AC66C3101

P478

Q33161840-3603B636-0BB1-439B-B2D5-4073552A1152

P50

Q33161840-25E96FAF-C83A-4BA4-A0D6-DFEFD8732DAF

Q33161840-F053684C-BD4F-4841-957C-89E134837818

P577

Q33161840-63AAF55C-A206-437C-B188-14451A242EB6

P698

Q33161840-FFEEB8B9-A72C-4435-AAD3-24F7F762D6C8

P356

ARCHPEDIATRICS.2012.1451

P1433

JAMA Pediatrics

P1476

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

@en

P2093

Bradley Ackerson

http://www.w3.org/2001/XMLSchema#string

Christine Velicer

http://www.w3.org/2001/XMLSchema#string

Chun Chao

http://www.w3.org/2001/XMLSchema#string

Harpreet Takhar

http://www.w3.org/2001/XMLSchema#string

Jeff Slezak

http://www.w3.org/2001/XMLSchema#string

John Hansen

http://www.w3.org/2001/XMLSchema#string

Kai-Li Liaw

http://www.w3.org/2001/XMLSchema#string

Kamala Deosaransingh

http://www.w3.org/2001/XMLSchema#string

Lina Sy

http://www.w3.org/2001/XMLSchema#string

Michael Emery

http://www.w3.org/2001/XMLSchema#string

P304

1140-1148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHPEDIATRICS.2012.1451

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P50

Steven J Jacobsen

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23027469

http://www.w3.org/2001/XMLSchema#string